The Orphan Drug Act was enacted in 1983 to stimulate drug development for rare diseases. How well this law has accomplished that goal is an important public health question. This study examined the characteristics of the 209 orphan drugs approved as new molecular entities in the period 1983-2014. As a whole, these drugs were highly innovative and provided substantial gains in reducing unmet medical needs for rare diseases: Over 50 percent of the drugs were first in class, and 78 percent received a priority review. Drugs approved as either therapeutic or supportive therapies for rare cancers represented the highest proportion of these drugs (35 percent). Additionally, in 2010-14 large companies became a strong presence in developing orphan new molecular entities for oncology indications. Overall, new orphan drugs appeared to be highly innovative and provided important advances in care for patients with rare diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1377/hlthaff.2015.0921 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Substrate transport and drug interaction of human thiamine transporters SLC19A2/A3.
Nat Commun
December 2024
ENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Department of Systems Biology for Medicine, Fudan University, Shanghai, China.
Thiamine and pyridoxine are essential B vitamins that serve as enzymatic cofactors in energy metabolism, protein and nucleic acid biosynthesis, and neurotransmitter production. In humans, thiamine transporters SLC19A2 and SLC19A3 primarily regulate cellular uptake of both vitamins. Genetic mutations in these transporters, which cause thiamine and pyridoxine deficiency, have been implicated in severe neurometabolic diseases.
View Article and Find Full Text PDFPurpose: The objective was to use cyclic tensile loading to compare the gap formation at suture site of three different suture materials to repair bovine radial meniscal tears: (1) polyglactin sutures, (2) tough adhesive puncture sealing (TAPS) sutures and (3) ultra-high molecular weight polyethylene (UHMWPE) sutures.
Methods: Twelve ex vivo bovine knees were dissected to retrieve the menisci. Complete radial tears were performed on 24 menisci, which were then separated into three groups and repaired using either pristine 2-0 polyglactin sutures, TAPS sutures (2-0 polyglactin sutures coated with adhesive chitosan/alginate hydrogels) or 2-0 UHMWPE sutures with a single stitch.
Phylogeography, taxonomy, and conservation of the endangered brown howler monkey, (Primates, Atelidae), of the Atlantic Forest.
Front Genet
December 2024
Programa de Pós-Graduação em Ecologia e Evolução da Biodiversidade, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
The brown howler, , endemic to the Atlantic Forest of Brazil and Argentina, is threatened by habitat loss and fragmentation, hunting, and its susceptibility to yellow fever. Two subspecies have been recognized, but their names, validity, and geographic ranges have been controversial. We obtained samples covering the species' entire distribution in Brazil and Argentina to clarify these issues by investigating their genetic diversity and structure and assessing their evolutionary history.
View Article and Find Full Text PDFMolecular Tracking of in an Archived Spleen Sample in Iran: A Case Report.
Iran J Parasitol
January 2024
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Rodents are the primary reservoir hosts for zoonotic cutaneous leishmaniasis (ZCL) caused by . Knowing reservoir hosts is crucial for leishmaniasis surveillance and control programs in endemic areas. In this study, we examined an archived spleen of obtained during a pest control program in 2000 in Tehran, the capital of Iran.
View Article and Find Full Text PDFThe Molecular Bacterial Load Assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif.
J Infect
December 2024
German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Division of Clinical Infectious Diseases, Research Center Borstel, Parkallee 1-40, 23845 Borstel, Germany.
Objectives: Early detection of treatment failure is essential to improve the management of drug-resistant tuberculosis (DR-TB). We evaluated the molecular bacterial load assay (MBLA) in comparison to standard diagnostic tests for monitoring therapy of patients affected by drug-resistant TB.
Methods: The performance of MBLA in tracking treatment response in a prospective cohort of patients with pulmonary MDR/RR- and pre-XDR/XDR-TB was compared with mycobacterial culture, mycobacterial DNA detection using GeneXpert (Xpert) and microscopy detection of sputum acid-fast-bacilli.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!